Moleculin Biotech's total assets for Q1 2026 were $23.36M, an increase of 5.59% from the previous quarter. MBRX total liabilities were $8.18M for the fiscal quarter, a 14.89% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.